ArticleNature genetics2014
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.
Article in Nature genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05832827 (First-line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas), which is not on this map. Cited by 148 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
First-line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas
Who cites it
148 citing papers in PubMed, 2 syntheses or guidelines pooled it, 256 citations in OpenAlex.
- Genomic landscape and subgroup stratification of thymic epithelial tumors: a systematic meta-analysis of next-generation sequencing data.Frontiers in oncology · 2026Pooled it
- Molecular profiling of rare thymoma using next-generation sequencing: meta-analysis.Radiology and oncology · 2023Pooled it
- Molecular predictors of response to pembrolizumab in thymic carcinoma.Cell reports. Medicine · 2021Trial
- Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.The Lancet. Oncology · 2018Trial
- Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.The Lancet. Oncology · 2015Trial
- Thymic epithelial tumors: what's next?Cancer metastasis reviews · 2026Review
- Distinct Associations ofGenes · 2026Article
- Brief Report: Androgen Receptor Expression Is Associated With Male Predominance in Thymic Neuroendocrine Neoplasms.JTO clinical and research reports · 2026Article
- Integrative Multiomic Classification Reveals Distinct Origins and Evolutionary Trajectories of Thymic Epithelial Tumors.Cancer research · 2026Article
- Characterization of tumour microenvironment in thymic epithelial tumours of different histological subtypes.Discover oncology · 2026Article
- Genome-wide analysis of somatic noncoding mutation patterns and mitochondrial heteroplasmic shift in type B1 and B2 thymomas.The Journal of pathology · 2026Article
- Evolving paradigms in thymoma surgery and multidisciplinary care: a narrative review.Mediastinum (Hong Kong, China) · 2026Review
- Atypical type A thymoma: a narrative review of a distinct and progressive variant of low-risk thymoma.Mediastinum (Hong Kong, China) · 2026Review
- Abscopal effect induced by conventional fractionated radiotherapy following anti-PD-1 immunotherapy in pulmonary metastatic thymic squamous cell carcinoma: a case report and literature review.Frontiers in immunology · 2026Review
- Galectin-7 as a biomarker for aggressiveness and poor prognosis in thymic epithelial tumors.Translational oncology · 2026Article
- Editorial: Advancing excellence in thoracic oncology: breakthroughs and impactful discoveries.Frontiers in oncology · 2026Article
- Pathobiology of thymic epithelial tumours and the treatment strategy based on immuno-oncological characteristics: a narrative review.Mediastinum (Hong Kong, China) · 2026Review
- Mediastinal epithelial neoplasms with recurrent molecular alterations.Mediastinum (Hong Kong, China) · 2026Review
- Article
- Somatic Mutations of Thymic Epithelial Tumors Identified in the Prospective THYMOGENE Trial.Thoracic cancer · 2025Article
88 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
22 authors at 5 institutions in 2 countries.
Funding
Abstract
We analyzed 28 thymic epithelial tumors (TETs) using next-generation sequencing and identified a missense mutation (chromosome 7 c.74146970T>A) in GTF2I at high frequency in type A thymomas, a relatively indolent subtype. In a series of 274 TETs, we detected the GTF2I mutation in 82% of type A and 74% of type AB thymomas but rarely in the aggressive subtypes, where recurrent mutations of known cancer genes have been identified. Therefore, GTF2I mutation correlated with better survival. GTF2I β and δ isoforms were expressed in TETs, and both mutant isoforms were able to stimulate cell proliferation in vitro. Thymic carcinomas carried a higher number of mutations than thymomas (average of 43.5 and 18.4, respectively). Notably, we identified recurrent mutations of known cancer genes, including TP53, CYLD, CDKN2A, BAP1 and PBRM1, in thymic carcinomas. These findings will complement the diagnostic assessment of these tumors and also facilitate development of a molecular classification and assessment of prognosis and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.